Yet, it was not until late 2017 that the Food and Drug Administration (FDA) approved LUXTURNA®, the first in vivo gene therapy product for RPE65-caused LCA (FDA 2017). The gene discussed is RPE65; the disease is Leber congenital amaurosis.